[Safety of influenza vaccination in asthmatics].

Pneumonol Alergol Pol

Klinika Pulmonologii i Alergologii Katedry Pneumonologii i Alergologii Uniwersytetu Medycznego w Łodzi, Poland.

Published: August 2007

The common cause of exacerbations in asthmatics are viral infections. Influenza infection especially increases the risk of respiratory exacerbations. The ACIP report puts asthma among indications to regular influenza vaccinations. In practice, many physicians doubt in effectiveness and safety of vaccination in patients suffering from allergy. It caused such procedures were not included in asthma guidelines published by other authors. Our study confirmed the safety of influenza split vaccine vaccination in asthmatics. We proved that vaccination had not any influence on asthma control in 14-day period after injection. We showed also high frequency of, mostly local, side effects. These events were generally mild and transient.

Download full-text PDF

Source

Publication Analysis

Top Keywords

[safety influenza
4
vaccination
4
influenza vaccination
4
vaccination asthmatics]
4
asthmatics] common
4
common exacerbations
4
exacerbations asthmatics
4
asthmatics viral
4
viral infections
4
infections influenza
4

Similar Publications

The influenza virus is classified as a single-stranded negative-sense RNA virus in Orthomyxoviridae family, with epidemiological properties distinct from common cold. Previous studies have found that influenza infection can cause cardiac damage through various pathways, and patients with cardiovascular diseases are at relatively higher risk of adverse disease outcomes. Influenza vaccination has been proven to provide protective effect on patients with cardiovascular diseases.

View Article and Find Full Text PDF

Safety Assessment of Influenza Vaccination for Neurological Outcomes Among Older Adults in Japan: A Self-Controlled Case Series Study.

Pharmacoepidemiol Drug Saf

January 2025

Department of Clinical Epidemiology & Health Economics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Purpose: To assess adverse neurological risks following influenza vaccination in older adults.

Methods: Using a linked database of healthcare administrative claims data and vaccination records from an urban city in Japan (April 1, 2014, to March 31, 2020), we conducted an observational study utilizing a self-controlled case series design. We identified individuals aged ≥ 65 years who experienced adverse neurological outcomes, defined as hospitalizations related to epilepsy, paralysis, facial paralysis, neuralgia, neuritis, optic neuritis, migraine, extrapyramidal disorders, Guillain-Barre syndrome, or narcolepsy.

View Article and Find Full Text PDF

Background And Aims: The recently approved maternal vaccination against respiratory syncytial virus (RSV) can reduce its burden among infants. However, vaccine hesitancy/resistance can undermine the beneficial impact of RSV vaccination. The aim of this study was to assess the willingness of pregnant women in Jordan to receive RSV vaccination and its associated determinants.

View Article and Find Full Text PDF

High quality research is critical for evidence-based decision making in public health and fundamental to maintain progress and trust in immunization programs in Europe. In 2024 the European Centre for Disease Prevention and Control (ECDC) conducted an update of the 2020 systematic review to capture more recent evidence on of the efficacy, effectiveness of influenza vaccines in individuals aged 18 years and older in the prevention of laboratory-confirmed influenza. While this report was highly anticipated due to the strength of the protocol and processes put in place, during our assessment, we expressed two chief concerns.

View Article and Find Full Text PDF

Introduction: Pediatric coronavirus disease 2019 (COVID-19) vaccination rates in the United States remain lower compared with adults. We aimed to (1) implement a quality improvement initiative to increase COVID-19 vaccination 2-fold in hospitalized patients 12-21 years of age from 4.7% during the baseline period (August 10, 2021-November 1, 2021) to 9.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!